Nebenwirkungen · Lenvima
LENVIMA 4 mg hard capsules LENVIMA 10 mg hard capsules · Abschnitt 4.8 · PDF-Seite 14
HOS-130563 · Präparat HOS-096939
In 496 patients with HCC, dose modification (interruption or reduction) and discontinuation were the actions taken for an adverse reaction in 62.3% and 20.2% of patients, respectively. Adverse reactions that most commonly led to dose modifications (in ≥5% of patients) were decreased appetite, diarrhoea, proteinuria, hypertension, fatigue, PPE and decreased platelet count. Adverse reactions that most commonly led to discontinuation of lenvatinib were hepatic encephalopathy, fatigue, increased blood bilirubin, proteinuria and hepatic failure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-26T15:37:00Z · SHA-256 1c91045dd7ec722373bf25329286d58d4e0b526fe9f67d03a2c83676cb980a84 · Passage 4e43bd62a53c0d250cbad8b9329a804279f5c5ec88aa932aee2ff4495445f18a · Zeichen 2397–2943 im Abschnitt